Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Seong Cho

Allergy & Immunology Tampa, FL Medical Doctor

NPI 1093917304 CMS profile 992717

13801 Bruce B Downs Blvd, Ste 502, Tampa, FL 33613

Open in the dashboard

General payments

$42,020

178 records reported · program years 2019–2025

Research payments

$18,086

Paid to them · 34 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$926,540 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Seong Cho of Tampa, FL is reported in the CMS Open Payments database as having received $42,020 across 178 general payments and $18,086 in research payments paid to them. Separately, studies naming them as principal investigator received $926,540 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,373 62
2025 Research $811 2
2024 General $6,915 43
2023 General $5,033 31
2023 Research $2,500 2
2022 General $8,719 14
2022 Research $1,750 5
2021 General $84 3
2021 Research $2,000 3
2020 General $49 3
2020 Research $6,260 8
2019 General $1,847 22
2019 Research $4,765 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seong Cho
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Seong Cho were reported at $19,373. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Seong Cho Allergy & Immunology median Middle half National median
2019 $1,847 $594 $163–$1,512 $163
2020 $49 $426 $106–$1,233 $114
2021 $84 $638 $157–$1,708 $132
2022 $8,719 $790 $205–$1,961 $149
2023 $5,033 $852 $220–$2,147 $160
2024 $6,915 $865 $203–$2,267 $164
2025 $19,373 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $12,895 30 payments
  2. Insmed, Inc. $12,201 7 payments
  3. Genzyme Corporation $5,781 20 payments
  4. AstraZeneca Pharmaceuticals LP $4,527 27 payments
  5. Regeneron Pharmaceuticals, Inc. $2,965 2 payments
  6. ALK-Abello, Inc $1,543 5 payments
  7. Regeneron Healthcare Solutions, Inc. $481 15 payments
  8. GlaxoSmithKline, LLC. $366 16 payments
  9. Pfizer Inc. $182 9 payments
  10. Genentech USA, Inc. $161 6 payments
  11. Other $920 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $30,131 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,750 5 payments
  3. Food and Beverage $4,484 150 payments
  4. Travel and Lodging $2,474 9 payments
  5. Education $182 3 payments
Products named General payments · program years 2019–2025
  1. Andembry $8,296 9 payments
  2. DUPIXENT Immunology $3,466 15 payments
  3. DUPIXENT Inflammation And Immunology $3,260 13 payments
  4. TEZSPIRE $1,867 4 payments
  5. Grastek $1,543 5 payments
  6. Ragwitek $1,543 5 payments
  7. Odactra $1,543 5 payments
  8. FASENRA $249 8 payments
  9. DUPIXENT Immunology And Inflammation $186 4 payments
  10. Haegarda $175 7 payments
  11. Other $2,061 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $11,025 22 payments
  2. Genzyme Corporation $6,250 10 payments
  3. Sanofi US Services Inc. $811 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

365

Median for Allergy/ Immunology: 449

Drug cost

$171,044

Median for Allergy/ Immunology: $169,700

Branded share of claims

45.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 20 $106,389
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $25,032
Breo Ellipta Fluticasone/Vilanterol Brand 21 $19,849
Arnuity Ellipta Fluticasone Furoate Brand 11 $8,619
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 20 $3,007
Cromolyn Sodium Generic 12 $1,813
Azelastine Hcl Generic 46 $1,737
Albuterol Sulfate Hfa Albuterol Sulfate Brand 36 $1,293
Ipratropium Bromide Generic 28 $933
Wixela Inhub Fluticasone Propion/Salmeterol Brand 11 $805

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$171,526

Of which drugs: $115,691

Medicare patients

199

Average age 73

Services billed

7,239

120 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 53%
Ischemic heart disease 35%
Diabetes 23%
COPD 23%
Osteoporosis 23%
Chronic kidney disease 19%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $1,909
  • Regeneron Healthcare Solutions, Inc. $25
$1,933 20 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $90
$90 32 —
XOLAIR
  • Genentech USA, Inc. $30
  • Novartis Pharmaceuticals Corporation $28
$58 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $55
$55 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record